Dyne Therapeutics, Inc. Common Stock DYN
Analyst Ratings
- Consensus
- Buy — 9 Buy · 2 Hold · 0 Sell (11 analysts)
- Avg. Price Target
- $35.56 (+75.1% upside)
Key Stats
- Today's Range
- $17.00 – $20.91
- 50-Day Range
- $17.00 – $27.30
- 52-Week Range
- $9.89 – $27.30
- Volume
- 17.17 million shs
- Average Volume
- 2.32 million shs
- Market Cap
- $3.79 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 5.40
- Price / Sales
- —
Short Interest
- Short Interest
- 11.72%
- Days to Cover
- 4.35
Financials (TTM)
- Revenue
- —
- Net Income
- $-519,406,000
- Net Margin
- —
- Return on Equity
- -73.97%
- Debt-to-Equity
- 0.28
About Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Related Stocks
Compare head-to-head: DYN vs LLY·DYN vs JNJ·DYN vs ABBV·DYN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.